“…This has been shown to reduce the cost of treatment by more than 50% without increasing adverse events or the need for drug monitoring [19,20]. Guidelines have suggested the use of CP as an alternative to CNI as the first line in SRNS [8,13]; however, previous reports as well as the current study show lower rates of response compared to CNI [10,21,22]. Delaying or not being able to provide optimum IS may worsen outcomes in regions where the options of effectively managing complications of persistent proteinuria, CKD, and KF are limited.…”